Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cells

Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cells

Abstract Despite promising preclinical and earlier clinical data, a recent phase III trial on the anti-β7 integrin antibody etrolizumab in Crohn’s disease (CD) did not reach its primary endpoint. The mechanisms leading to this outcome are not well understood. Here we characterize the β7+ T cell comp...

Popoln opis

Bibliografske podrobnosti
Main Authors: Maximilian Wiendl, Mark Dedden, Li-Juan Liu, Anna Schweda, Eva-Maria Paap, Karen A.-M. Ullrich, Leonie Hartmann, Luisa Wieser, Francesco Vitali, Imke Atreya, Tanja M. Müller, Claudia Günther, Raja Atreya, Markus F. Neurath, Sebastian Zundler
Format: Article
Jezik:English
Izdano: Nature Portfolio 2024-02-01
Serija:Nature Communications
Online dostop:https://doi.org/10.1038/s41467-024-45352-6

Internet

https://doi.org/10.1038/s41467-024-45352-6

Podobne knjige/članki